Core Points - Rosen Law Firm is reminding investors who purchased Marex Group plc securities between May 16, 2024, and August 5, 2025, of the December 8, 2025, lead plaintiff deadline for a class action lawsuit [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] Company Details - The lawsuit alleges that Marex made materially false and misleading statements, including selling over-the-counter financial instruments to itself and inconsistencies in financial statements between subsidiaries [4] - The misleading statements led to investors suffering damages when the true details were revealed [4] Legal Representation - Investors are encouraged to select qualified counsel with a successful track record in securities class actions, as many firms may not have the necessary experience [3] - Rosen Law Firm has a history of significant recoveries for investors, including over $438 million in 2019 alone [3]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Marex Group plc due to allegations of securities law violations, encouraging affected investors to contact them directly [1][3][4]. Group 1: Allegations Against Marex - The complaint alleges that Marex and its executives made false or misleading statements and failed to disclose critical information, including the sale of over-the-counter financial instruments to itself and inconsistencies in financial statements [3]. - A report from NINGI Research accused Marex of a multi-year accounting scheme involving off-balance-sheet entities and fictitious transactions to hide losses and inflate profits, citing a fabricated receivable of $17 million and nearly $1 billion in concealed derivatives exposure [4]. - Following the release of the report, Marex's stock experienced a significant decline of 6.2%, closing at $35.31 on heavy trading volume [5]. Group 2: Legal Proceedings and Investor Actions - The deadline for investors to seek the role of lead plaintiff in the federal securities class action against Marex is December 8, 2025, with the lead plaintiff being the investor with the largest financial interest [1][6]. - Faruqi & Faruqi encourages anyone with information regarding Marex's conduct, including whistleblowers and former employees, to come forward [6].

Core Viewpoint - Marex Group PLC is facing a class action lawsuit for allegedly misleading investors about its revenue projections and inflating its financial metrics through improper transactions [2][3]. Group 1: Company Overview - Marex Group PLC is a U.K.-based diversified global financial services platform listed on NASDAQ under the ticker MRX [1]. Group 2: Legal Allegations - The lawsuit claims that Marex Group failed to disclose that it improperly inflated its cash flow, revenues, assets, and profits in its Market Making segment through off-book intercompany transactions [3]. - As a result of these alleged actions, investors who sold short Marex Group securities during the class period have reportedly suffered significant losses [3]. Group 3: Class Action Participation - Shareholders who wish to serve as lead plaintiffs in the class action must submit their papers to the court by December 8, 2025 [4]. - Participation in the class action is not mandatory for recovery; shareholders can remain absent class members if they choose not to take action [4]. Group 4: Legal Representation - Robbins LLP, a firm specializing in shareholder rights litigation, is representing the class action on a contingency fee basis, meaning shareholders pay no fees or expenses unless there is a recovery [5].

Core Viewpoint - A class action lawsuit has been filed against Marex Group plc, alleging that the company concealed losses and inflated profits through deceptive financial practices during the specified class period [1][3]. Group 1: Lawsuit Details - The lawsuit is initiated by Berger Montague on behalf of investors who purchased Marex shares from May 16, 2024, to August 5, 2025 [1][2]. - Investors have until December 8, 2025, to seek appointment as lead plaintiff representatives [2]. Group 2: Allegations and Impact - NINGI Research published a report on August 5, 2025, claiming that Marex used off-balance-sheet entities and fictitious intercompany transactions to hide losses and inflate profits [3]. - Following the report, Marex's stock price fell by $2.33, or 6.2%, closing at $35.31, resulting in significant investor losses [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Marex Group plc during the specified Class Period of the upcoming lead plaintiff deadline on December 8, 2025, and the potential for compensation through a contingency fee arrangement [1][2]. Group 1: Class Action Details - The class action lawsuit against Marex Group plc alleges that during the Class Period, the company made materially false and misleading statements and failed to disclose critical information regarding its financial practices [4]. - Specific allegations include Marex selling over-the-counter financial instruments to itself, inconsistencies in financial statements between subsidiaries, and the unreliability of Marex's financial statements [4]. - The lawsuit claims that these misrepresentations led to investor damages when the true details became public [4]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [3]. - Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions for investors [3]. - The firm was ranked No. 1 for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013 [3].

Core Viewpoint - Class action lawsuits have been filed on behalf of shareholders of several publicly-traded companies, with specific allegations of misleading statements and undisclosed adverse facts regarding their business operations and prospects [1]. Group 1: Marex Group plc (NASDAQ: MRX) - The class period for Marex Group is from May 16, 2024, to August 5, 2025, with a lead plaintiff deadline of December 8, 2025 [2]. - Allegations include that the company sold over-the-counter financial instruments to itself and had inconsistencies in financial statements between subsidiaries and related parties, leading to unreliable financial statements [2]. - Defendants' positive statements about the company's business were deemed materially misleading due to these undisclosed facts [2]. Group 2: aTyr Pharma Inc. (NASDAQ: ATYR) - The class period for aTyr Pharma is from January 16, 2025, to September 12, 2025, with a lead plaintiff deadline of December 8, 2025 [3]. - The complaint alleges that defendants misrepresented the study design for EFZO-FIT, creating a false impression that the drug would meet its primary endpoint [3]. - Positive statements regarding the company's business were considered materially misleading as the Phase 3 study did not meet its primary endpoint [3]. Group 3: WPP plc (NYSE: WPP) - The class period for WPP is from February 27, 2025, to July 8, 2025, with a lead plaintiff deadline of December 8, 2025 [4]. - Allegations state that WPP's media arm was not equipped to handle macroeconomic challenges and was losing market share to competitors [4]. - Defendants' positive statements about the company's business operations were found to be materially misleading due to these undisclosed challenges [4].

Core Points - Rosen Law Firm is reminding investors who purchased Marex Group plc securities between May 16, 2024, and August 5, 2025, of the December 8, 2025, lead plaintiff deadline for a class action lawsuit [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] Company Details - The lawsuit alleges that Marex made materially false and misleading statements, including selling over-the-counter financial instruments to itself and inconsistencies in financial statements between subsidiaries [4] - The misleading statements led to investors suffering damages when the true details were revealed [4] Legal Representation - Investors are encouraged to select qualified counsel with a successful track record in securities class actions, as many firms may not have the necessary experience [3] - Rosen Law Firm has a history of significant recoveries for investors, including over $438 million in 2019 alone [3]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Marex Group plc due to allegations of securities law violations, with a deadline for investors to seek lead plaintiff status by December 8, 2025 [1][3]. Group 1: Allegations Against Marex - The complaint alleges that Marex and its executives made false and misleading statements, including selling over-the-counter financial instruments to itself and inconsistencies in financial statements [3]. - A report from NINGI Research accused Marex of a multi-year accounting scheme involving off-balance-sheet entities and fictitious transactions, including a fabricated receivable of $17 million and nearly $1 billion in concealed derivatives exposure [4]. - Following the release of the report, Marex's stock experienced a decline of 6.2%, closing at $35.31 on heavy trading volume [5]. Group 2: Legal Proceedings and Investor Actions - The lead plaintiff in the class action lawsuit will be the investor with the largest financial interest who is adequate and typical of class members, and any member of the class may move to serve as lead plaintiff [6]. - Faruqi & Faruqi encourages individuals with information regarding Marex's conduct, including whistleblowers and former employees, to contact the firm [6].

Core Viewpoint - Marex Group plc is set to release its fiscal 2025 third quarter results on November 6, 2025, before market opening, indicating a commitment to transparency and investor communication [1] Company Overview - Marex Group plc (NASDAQ: MRX) operates as a diversified global financial services platform, providing essential liquidity, market access, and infrastructure services across energy, commodities, and financial markets [2] - The company offers a comprehensive range of services, including Clearing, Agency and Execution, Market Making, and Hedging and Investment Solutions, with a strong presence in major metals, energy, and agricultural products [2] - Marex has access to 60 exchanges and serves a diverse client base, including large commodity producers, consumers, traders, banks, hedge funds, and asset managers [2] - The company operates over 40 offices globally, employing more than 2,400 staff across Europe, Asia, and the Americas [2]

Core Viewpoint - Rosen Law Firm has announced the filing of a class action lawsuit on behalf of purchasers of Marex Group plc securities during the specified Class Period, indicating potential legal issues surrounding the company's financial disclosures and practices [1][5]. Group 1: Class Action Details - The class action lawsuit is on behalf of purchasers of Marex securities between May 16, 2024, and August 5, 2025, and a previous class action has already been filed [1]. - Investors who purchased Marex securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by submitting a form or contacting the law firm directly, with a deadline to serve as lead plaintiff set for December 8, 2025 [3][6]. Group 2: Allegations Against Marex - The lawsuit alleges that Marex made materially false and misleading statements and failed to disclose critical information, including the sale of over-the-counter financial instruments to itself and inconsistencies in financial statements [5]. - It is claimed that Marex's financial statements could not be relied upon due to these issues, leading to misleading positive statements about the company's business and operations [5].